Literature DB >> 31202868

Functional surgery versus amputation for in situ or minimally invasive nail melanoma: A meta-analysis.

Gwanghyun Jo1, Soo Ick Cho1, Sungjun Choi1, Je-Ho Mun2.   

Abstract

BACKGROUND: Evidence on whether functional surgery is not inferior to amputation for the treatment of in situ or minimally invasive (Breslow thickness ≤0.5 mm) nail melanoma is limited.
OBJECTIVE: To investigate the difference in local recurrence between the 2 interventions for in situ or minimally invasive nail melanoma using available published studies.
METHODS: We performed systematic search on PubMed, Embase, Cochrane Library, trial registers, and grey literature databases from inception to June 28, 2018. We included observational studies with at least 5 patients with in situ or minimally invasive nail melanoma. Main outcome was local recurrence.
RESULTS: The odds ratio synthesized from 5 studies including 109 patients (88 functional operations and 21 amputations) was 1.57 (95% confidence interval, 0.31-8.00). LIMITATIONS: Small sample size and possible interstudy heterogeneity.
CONCLUSIONS: Our meta-analysis revealed no difference in local recurrence between the 2 interventions. Considering the functional deficit after amputation, conservative surgery should be the treatment of choice for in situ or minimally invasive nail melanoma.
Copyright © 2019 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  amputation; conservative surgery; functional surgery; melanoma; melanoma in situ; meta-analysis; nail disease; recurrence

Mesh:

Year:  2019        PMID: 31202868     DOI: 10.1016/j.jaad.2019.06.012

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  1 in total

1.  Secondary Intention Healing After Functional Surgery for in Situ or Minimally Invasive Nail Melanoma.

Authors:  Gwanghyun Jo; Keunyoung Hur; Soo Ick Cho; Je-Ho Mun
Journal:  Acta Derm Venereol       Date:  2020-06-11       Impact factor: 3.875

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.